Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kao, W.H. L.
Right arrow Articles by Brancati, F. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kao, W.H. L.
Right arrow Articles by Brancati, F. L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 52:1568-1572, 2003
© 2003 by the American Diabetes Association, Inc.

Brief Genetics Reports

Pro12Ala of the Peroxisome Proliferator–Activated Receptor-{gamma}2 Gene Is Associated With Lower Serum Insulin Levels in Nonobese African Americans

The Atherosclerosis Risk in Communities Study

W.H. Linda Kao1, Josef Coresh1,2, Alan R. Shuldiner3, Eric Boerwinkle4, Molly S. Bray4, and Frederick L. Brancati1,2

1 Department of Epidemiology, the Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland
2 Department of Medicine, the Johns Hopkins University School of Medicine, Baltimore, Maryland
3 Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, and Baltimore Veterans Hospital Geriatrics Research and Education Clinical Center, Baltimore, Maryland
4 Human Genetics Center, Institute of Molecular Medicine, University of Texas Houston Health Science Center, Houston, Texas


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESULTS
 DISCUSSION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 
Recent research suggests that the Pro12Ala variant in peroxisome proliferator–activated receptor-{gamma}2 (PPAR-{gamma}2) is associated with diabetes- and obesity-related traits, and that its effects may be modified by obesity status. We characterized this variant in a population-based sample of 1,441 middle-aged African-American individuals with respect to diabetes-, obesity-, and other cardiovascular-related traits, both cross-sectionally and prospectively. The overall frequency of Ala12 was 1.9% (95% CI 1.5–2.5%), significantly lower than in Caucasian populations. Consistent with previous findings in Caucasians, African Americans with type 2 diabetes tended to be less likely to have the Pro/Ala genotype than those without (odds ratio [OR] 0.64, 95% CI 0.34–1.20); however, this OR was not statistically significant. Among nonobese individuals, the Pro/Ala genotype was associated with significantly lower ln(insulin) (P = 0.001), lower ln(HOMA-IR) (homeostasis model assessment of insulin resistance) (P = 0.002), higher fasting glucose-to-insulin ratio (P = 0.005), and lower diastolic blood pressure (P = 0.02). Among overweight individuals (BMI 25–29.9 kg/m2), the Pro/Ala genotype was associated with greater BMI (P = 0.02), waist-to-hip ratio (P = 0.01), and waist circumference (P = 0.04). Among obese individuals, there was no association between any of the diabetes- or obesity-related traits and the Pro12Ala PPAR-{gamma}2 variant. We conclude that among nonobese African Americans, the Pro/Ala genotype is associated with markers of greater insulin sensitivity.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESULTS
 DISCUSSION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 
Peroxisome proliferator–activated receptor-{gamma}2 (PPAR-{gamma}2) is a transcription factor that is expressed predominantly in adipose tissues and is believed to have a critical role in adipogenesis and insulin action (1,2). A nonconservative substitution at codon 12 (Pro12Ala) was identified (3), and several association studies have been conducted to examine the associations between the Pro12Ala variant and adiposity or type 2 diabetes (4–25). The results have been mixed; one of the more consistent findings is the association of the Ala12 allele and insulin sensitivity (5,10,12,24) and protection from type 2 diabetes (16,26) while several studies have raised the possibility of an interaction among the Pro12Ala PPAR-{gamma}2 variant, obesity, and insulin action (4,6,10). Little is known about this variant in African Americans. Since ethnicity-related genetic background may affect the phenotypic expression of a given susceptibility gene variant, we characterized this variant in a population-based sample of middle-aged African-American individuals with respect to diabetes-, obesity-, and other cardiovascular-related traits.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
DISCUSSION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 
A total of 1,441 African-American Atherosclerosis Risk in Communities (ARIC) participants were included in the present study. The participants age was 53.4 ± 5.8 years (means ± SD), 40% were men, 86% were from Jackson, MS, and the mean BMI was 29.0 ± 5.8 kg/m2.

Unlike in Caucasian populations, Ala12 of PPAR-{gamma}2 is a relatively rare allele in this population. The overall frequency of the Ala allele in our African-American subjects was 1.9% (95% CI 1.5–2.5%). The genotype distribution was in accordance with Hardy-Weinberg expectation, and no Ala/Ala homozygotes were found.

Association between Pro12Ala PPAR-{gamma}2 and type 2 diabetes.
There were 269 individuals with type 2 diabetes at baseline and 167 individuals who developed type 2 diabetes during follow-up, leaving 1,005 diabetes-free individuals. The Pro12Ala variant was not significantly associated with diabetes at the P = 0.05 level (Table 1). However, in all analyses, diabetes tended to be less frequent in participants with the Pro/Ala genotype. After adjusting for age and sex, the odds ratio (OR) for type 2 diabetes associated with the Pro/Ala genotype was 0.64 (95% CI 0.34–1.20). No significant interaction between genotype and sex or obesity on type 2 diabetes risk was detected.


View this table:
[in this window]
[in a new window]
  		TABLE 1 Allele frequency and genotype distribution of Pro12Ala, by diabetes status, in 1,441 African-American ARIC participants

 
Association between Pro12Ala PPAR-{gamma}2 and selected cardiovascular risk factors.
In 1,172 nondiabetic individuals, the Pro12Ala variant was not associated with either obesity- or diabetes-related traits at baseline; however, Pro/Ala genotype was associated with lower diastolic blood pressure (Table 2). After excluding 427 individuals who were taking blood pressure–lowering medications, the age- and sex-adjusted diastolic blood pressure was 78.2 mmHg for Pro/Pro and 73.1 mmHg for Pro/Ala groups (P = 0.02). Similarly, individuals with the Pro/Ala genotype had lower systolic blood pressure than those with the Pro/Pro genotype, but this difference was not statistically significant.


View this table:
[in this window]
[in a new window]
  		TABLE 2 Adjusted mean in 1,172 nondiabetic African-American ARIC participants by Pro12Ala genotype

 
Interaction between Pro12Ala PPAR-{gamma}2, markers for obesity, and insulin sensitivity.
Table 3 summarizes the association between the Pro12Ala variant and selected traits by obesity status at visit 1 of the study. Among individuals with BMI <25 kg/m2, those with the Pro/Ala genotype had higher mean BMI, waist-to-hip ratio, and waist circumference than those with the Pro/Pro genotype, but none of the associations were significant at the P = 0.05 level. Pro/Ala genotype was associated with significantly lower insulin (P = 0.001), lower homeostasis model assessment of insulin resistance (HOMA-IR) index (P = 0.002), and higher fasting glucose-to-insulin ratio (P = 0.005), all indicating greater insulin sensitivity in those with the Pro/Ala genotype. The results remained unchanged after further adjustment for BMI within each category. Treating BMI as a continuous trait, we examined a different interaction model of insulin sensitivity, Pro12Ala genotype, and obesity by modeling log(insulin) as the dependent variable and age, sex, BMI, and Pro12Ala genotype as the independent variables. We found that the association between insulin and BMI differs depending on the Pro12Ala genotype (P = 0.0027).


View this table:
[in this window]
[in a new window]
  		TABLE 3 Associations between selected quantitative traits (mean) and Pro12Ala genotype in 1,172 nondiabetic African-American ARIC participants by obesity status

 
Among overweight individuals (BMI 25–29.9 kg/m2), the Pro/Ala genotype was also associated with obesity measures (Table 3). Overweight individuals with the Pro/Ala genotype had greater BMI (P = 0.02), waist-to-hip ratio (P = 0.01), and waist circumference (P = 0.004) than overweight individuals with the Pro/Pro genotype. There was no association between the Pro12Ala variant and any of the markers for insulin resistance among overweight individuals. Among obese individuals (BMI >=30 kg/m2), there was no association between any of the diabetes- or obesity-related traits and the Pro12Ala variant.

Longitudinal analysis of Pro12Ala PPAR-{gamma}2 and selected cardiovascular risk factors.
Since the Pro12Ala variant was associated with insulin levels among the 329 individuals with BMI <25 kg/m2 at visit 1, we next examined this association prospectively. Of these 329 individuals, 185 were followed to visit 4 and were diabetes-free at visit 4 (n = 177 for Pro/Pro and n = 8 for Pro/Ala). There were no significant differences in the rate of change in insulin or glucose measures between Pro/Pro and Pro/Ala groups (results not shown).

Since the Pro12Ala variant was associated with measures of obesity among the 451 overweight individuals at Visit 1, we also examined the association between Pro12Ala PPAR-{gamma}2 and obesity measurements from follow-up visits in these individuals (Table 4). The Pro/Ala genotype was associated with increased BMI, waist-to-hip ratio, and waist circumference during the follow-up visits. For any given visit of the study, Pro/Ala genotype was associated with higher BMI (P = 0.03), waist-to-hip ratio (P = 0.01), and waist circumference (P = 0.006). Although the mean values of these traits in the follow-up visits differed between genotypes, the rate of change (e.g., change in BMI per 3 years) in these obesity-related traits over follow-up did not differ significantly between genotypes.


View this table:
[in this window]
[in a new window]
  		TABLE 4 Analysis of selected quantitative traits from follow-up visits by PPAR-{gamma}2 genotypes in 451 overweight African-American ARIC participants

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
RESEARCH DESIGN AND METHODS
 REFERENCES
 
The data lead to two main conclusions about the Pro12Ala PPAR-{gamma}2 variant in African Americans. First, the Ala12 allele was associated with markers of greater insulin sensitivity in nonobese individuals. Second, the Ala12 allele tended to be associated with a lower prevalence of type 2 diabetes. Although the magnitude of this association was similar to those described by others (5,12,16,16,26–28), it was not statistically significant due to the low frequency of the Ala allele in this population.

Limitations of our study include limited characterization of insulin resistance, possibility of false positive associations due to type 1 error, small sample size for analyses of qualitative traits given the low allele frequency of the Ala12 allele, and the lack of observations regarding homozygosity for this allele. Furthermore, the Pro12Ala variant may be in linkage disequilibrium with a nearby variant in PPAR-{gamma}2 or a nearby gene. Nonetheless, the uniqueness of this understudied study population and the collection of longitudinal data add strength to this study.

One of the most consistent associations of the Pro12Ala variant among studies is that of the Ala12 allele and increased insulin sensitivity. This has been shown in several nondiabetic populations (5,10,12,17,19,20,29). In addition, the Pro12Ala polymorphism is associated with increased insulin sensitivity of glucose disposal and suppression of lipolysis (30). In our study, the Pro/Ala genotype was associated with insulin sensitivity only among the nonobese African-American individuals. The lack of association between the Pro/Ala genotype and insulin sensitivity in obese individuals could be attributed to increased environmental influences, additional unknown genetic influences in this group, or the confounding influences of obesity itself (25).

While some studies have observed either no significant association between type 2 diabetes and this variant (7,8,11) or increased diabetes risk with the Ala12 allele (21), we observed a decrease in the prevalence of diabetes among African Americans with the Pro/Ala genotype. The magnitude of this association was similar to those found in Japanese (5,12,27), Scandinavian (16,28), U.S., and Polish populations (26). In addition, a study that pooled previous smaller studies of this association showed that the Pro/Ala genotype is associated with decreased diabetes prevalence (16). Protection from diabetes is consistent with our findings and those of others showing increased insulin sensitivity in subjects with the Pro/Ala genotype.

Positive (4,11,14,20), null (8,9,12,13,15), and negative associations (5) between the Pro/Ala genotype and obesity measures have also been reported in various populations. A possible explanation for the inconsistencies was suggested by the study of Ek et al. (6), in which the Ala12 allele was associated with lower BMI in nonobese subjects and higher BMI in obese subjects, and by Luan et al. (31), in which interaction between the Ala12 allele and dietary fat intake on insulin sensitivity and BMI was observed. These interactions are not unlikely in light of the highly codependent relationship between PPAR-{gamma}2 and adipocytes, as well as the fact that some dietary fats are ligands for PPAR-{gamma}2.

In summary, results from our study indicate significant association between the Pro/Ala genotype of PPAR-{gamma}2 and markers of insulin sensitivity and perhaps also protection from the development of type 2 diabetes among nonobese African-American individuals. It is clear that the physiologic roles of PPAR-{gamma}2 are numerous and that complex mechanisms exist for the associations between PPAR-{gamma}2 and increased adiposity and between PPAR-{gamma}2 and increased insulin sensitivity. Further studies are warranted to investigate the cellular and molecular mechanisms underlying these associations.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 RESEARCH DESIGN AND METHODS
REFERENCES
 
Setting and study participants.
Subjects of the present analyses were selected from the 4,266 African-American participants of ARIC study. The ARIC study is a prospective epidemiologic study that examines clinical and subclinical atherosclerotic disease in a cohort of 15,792 persons, aged 45–64 years at baseline examination, selected by probability sampling from four U.S. communities: Forsyth County, NC (12% African American); Jackson, MS (100% African American); the northwest suburbs of Minneapolis, MN (<1% African American); and Washington County, MD (<1% African American). The sampling procedure and methods used in ARIC have been described in detail elsewhere (32). The present analyses included four clinic visits that were scheduled 3 years apart (visit 1–4). Classification of ethnicity was based on self-report. African-American individuals were excluded from the sampling frame of the present analyses if they had missing demographic, clinical, dietary, or laboratory data at baseline (n = 998), resulting in a sampling frame of 3,268 individuals (2,006 women and 1,262 men). Using sex-stratified simple random sampling, 1,441 individuals were selected for the present analyses (sampling fraction = 44%).

Diabetes was defined as the presence of any one of the following at visits 1–4 of the study: 1) fasting glucose >=7.0 mmol/l (126 mg/dl), 2) nonfasting glucose >=11.1 mmol/l (200 mg/dl), 3) current use of diabetic medication, or 4) a positive response to the question "Has a doctor ever told you that you had diabetes (sugar in the blood)?"

Exposure assessment.
Baseline examination included home interviews, clinic examinations, and clinic questionnaires. Information on age, sex, race, family history of diabetes, and education were obtained from the home and clinic interviews conducted at the baseline visit. Anthropometry was performed at the baseline clinic visit, and each of the three subsequent visits, with the participants wearing light-weight, nonconstricting underwear and no shoes. Waist and hip girths were measured using an anthropometric tape applied at the level of umbilicus and of the maximal protrusion of the gluteal muscles, respectively. The reliability of girth measurements were high. Physical activity during leisure time was assessed by an index (1 = least active and 5 = most active) derived from a modified interviewer-administered version of the questionnaire developed by Baecke et al. (33) measuring usual activities. Dietary intake was also assessed by an interviewer-administered, modified version of the 61-item food frequency questionnaire developed by Willett et al. (34) from which total energy intake was calculated.

Serum glucose was assessed by a modified hexokinase/glucose-6-phosphate dehydrogenase procedure, a Centers for Disease Control and Prevention national glucose reference method. Standard radioimmunoassay was used to determine serum insulin (125I Insulin [732] kit; Cambridge Medical Diagnostics, Billerica, MA). The formula for the HOMA model was as follow: HOMA-IR = [fasting insulin (uU/ml) x fasting glucose(mmol/l)/22.5].

PCR amplification of a 270-bp fragment containing the Pro12Ala variant of PPAR-{gamma}2 was performed using standard PCR protocol and Ready-To-Go PCR bead (Pharmacia Biotech, Uppsala, Sweden) with 1.5 mmol/l magnesium. The PCR product was resolved on a 2% Nusieve:1% agarose gel with ethidium bromide in Tris-borate EDTA buffer (88 mmol/l Tris, 88 mmol/l boric acid, and 2 mmol/l EDTA).

A subset of 75 duplicate samples was genotyped for quality control of the assays, and the {kappa} statistic was 1.0 for each gene variant. Interreader reliability of the scoring of the samples was assessed by having another member of the lab, who was blinded to the phenotypes being studied, independently score a random sample for both gene variants. The interreader {kappa} statistic was 1.0 for the Pro12Ala PPAR-{gamma}2 variant (n = 96).

Statistical analysis.
Means ± SD and frequencies of baseline characteristics were calculated. Since fasting serum insulin and triglyceride levels and HOMA-IR indices were not normally distributed, they were ln-transformed for analysis, but geometric means were presented in the results tables. Allele frequencies were calculated, and two-sample test for binomial proportions was used to assess differences in allele frequencies between prevalent diabetic and nondiabetic individuals and between all diabetic and nondiabetic individuals. Fisher’s exact test was used to assess difference in allele frequencies between incident diabetic and nondiabetic individuals due to the small number of diabetic individuals with Pro/Ala genotype. {chi}2 goodness-of-fit test was used to assess deviation from Hardy-Weinberg equilibrium of the genotypic frequency by calculating expected frequencies of genotypes. Multiple logistic regression was used to adjust for age, sex, and other potential confounders, and ORs (with 95% Cis) for diabetes were reported. Individuals were classified as nonobese, overweight, or obese according to their BMI at baseline using the following cutoff values: BMI <25 kg/m2 was nonobese, BMI 25–30 was overweight, and BMI >=30 was obese. Gene-by-environment interactions among obesity-related traits, environmental exposures (physical activity, total fat intake, total polyunsaturated fatty acid, or total energy intake), and Pro12Ala genotypes were assessed by regressing the obesity-related trait (e.g., BMI) on the environmental exposure (e.g., physical activity index, Pro12Ala genotypes, and an interaction term that allowed for genotype-specific slope for the association between the environmental variable and the obesity-related outcome).

Since obesity-related quantitative traits were measured at each of the four visits of the study, a random effects model was fitted to assess the association between genotype and changes in obesity-related quantitative traits from visit 1 to 4 of the study. Analyses of longitudinal data were performed using Stata statistical package (College Station, TX), and all other statistical analyses were performed using the SAS statistical package (Cary, NC).


   ACKNOWLEDGMENTS
 
This research was supported by National Institutes of Health (NIH) grant 1R01DK53959-01. F.L.B. was supported by a Established Investigator Grant from the American Heart Association, Dallas, TX, and by NIH grant 1K24-DK6222-01. W.H.L.K. was supported by NIH training grant T32HL07024-23. A.R.S. was supported by NIH grant K24DK02673 and the Baltimore Veterans Administration Geriatrics Research and Education Center. The ARIC Study is carried out as a collaborative study supported by contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022 from the National Heart, Lung, and Blood Institute.

The authors thank the staff and participants in the ARIC study for their important contributions.


   FOOTNOTES
 
Address correspondence and reprint requests to Dr. W.H. Linda Kao, Department of Epidemiology, the Johns Hopkins University, 615 N. Wolfe St., Room W6513, Baltimore, MD 21205. E-mail: wkao{at}jhsph.edu.

Received for publication 29 August 2002 and accepted in revised form 18 February 2003.

ARIC, Atherosclerosis Risk in Communities; HOMA-IR, homeostasis model assessment of insulin resistance; PPAR-{gamma}2, peroxisome proliferator–activated receptor-{gamma}2.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 

  1. Beamer BA, Negri C, Yen CJ, Gavrilova O, Rumberger JM, Durcan MJ, Yarnall DP, Hawkins AL, Griffin CA, Burns DK, Roth J, Reitman M, Shuldiner AR: Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun233 :756 –759,1997[Medline]
  2. Spiegelman BM, Hu E, Kim JB, Brun R: PPAR gamma and the control of adipogenesis. Biochimie79 :111 –112,1997[Medline]
  3. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun241 :270 –274,1997[Medline]
  4. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR: Association of the Pro12Ala variant in the peroxisome proliferator–activated receptor-{gamma}2 gene with obesity in two Caucasian populations. Diabetes47 :1806 –1808,1998[Medline]
  5. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet20 :284 –287,1998[Medline]
  6. Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J, Pedersen O: Homozygosity of the Pro12Ala variant of the peroxisome proliferation- activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia42 :892 –895,1999[Medline]
  7. Ringel J, Engeli S, Distler A, Sharma AM: Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun254 :450 –453,1999[Medline]
  8. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V: Pro12Ala substitution in the peroxisome proliferator–activated receptor-{gamma}2 is not associated with type 2 diabetes. Diabetes48 :1466 –1468,1999[Abstract]
  9. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA, Shuldiner AR, Akanuma Y, Yazaki Y, Kadowaki T: Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men Biochem Biophys Res Commun251 :195 –198,1998[Medline]
  10. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Renn W, Haring HU: The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia42 :758 –762,1999[Medline]
  11. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P: Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord24 :195 –199,2000[Medline]
  12. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T: The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun271 :212 –216,2000[Medline]
  13. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C: The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord24 :391 –393,2000[Medline]
  14. Cole SA, Mitchell BD, Hsueh WC, Pineda P, Beamer BA, Shuldiner AR, Comuzzie AG, Blangero J, Hixson JE: The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord24 :522 –524,2000[Medline]
  15. Evans D, Mann WA, Heer J, Michel U, Wendt D, Kortner B, Wolf A, Beisiegel U: Variation in the gene for human peroxisome proliferator activated receptor gamma (PPARgamma) does not play a major role in the development of morbid obesity. Int J Obes Relat Metab Disord24 :647 –651,2000[Medline]
  16. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet26 :76 –80,2000[Medline]
  17. Eriksson JG, Lindi V, Uusitupa M, Forsen TJ, Laakso M, Osmond C, Barker DJ: The effects of the Pro12Ala polymorphism of the peroxisome proliferator–activated receptor-{gamma}2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes51 :2321 –2324,2002[Abstract/Free Full Text]
  18. Chuang LM, Hsiung CA, Chen YD, Ho LT, Sheu WH, Pei D, Nakatsuka CH, Cox D, Pratt RE, Lei HH, Tai TY: Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study: Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. J Mol Med79 :656 –664,2001[Medline]
  19. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O: Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia44 :1170 –1176,2001[Medline]
  20. Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa MI: Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia44 :925 –926,2001[Medline]
  21. Lindi VI, Uusitupa MI, Lindstrom J, Louheranta A, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Tuomilehto J: Association of the Pro12Ala polymorphism in the PPAR-{gamma}2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes51 :2581 –2586,2002[Abstract/Free Full Text]
  22. Stumvoll M, Haring H: The peroxisome proliferator–activated receptor-{gamma}2 Pro12Ala polymorphism. Diabetes51 :2341 –2347,2002[Abstract/Free Full Text]
  23. Celi FS, Shuldiner AR: The role of peroxisome proliferator–activated receptor gamma in diabetes and obesity. Curr Diab Rep2 :179 –185,2002[Medline]
  24. Stumvoll M, Wahl HG, Loblein K, Hauer B, Grauer P, Becker R, Rett K, Machicao F, Jacob S, Haring H: The Pro12Ala polymorphism in the peroxisome proliferator activated receptor {gamma}2 gene is associated with increased antilipolytic insulin sensitivity in lean, healthy subjects (Abstract). Diabetes49 (Suppl. 1) :A7 ,2000
  25. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR: Genetic variation in the peroxisome proliferator–activated receptor-{gamma}2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes50 :2172 –2176,2001[Abstract/Free Full Text]
  26. Ardlie KG, Lunetta KL, Seielstad M: Testing for population subdivision and association in four case-control studies. Am J Hum Genet71 :304 –311,2002[Medline]
  27. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M: The Pro12->Ala substitution in PPAR-{gamma} is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes50 :891 –894,2001[Abstract/Free Full Text]
  28. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J: The peroxisome proliferator–activated receptor-{gamma}2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes50 :886 –890,2001[Abstract/Free Full Text]
  29. Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z, Gonano F, Bartoli E: Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res30 :146 –149,1998[Medline]
  30. Stumvoll M, Wahl HG, Loblein K, Becker R, Machicao F, Jacob S, Haring H: Pro12Ala polymorphism in the peroxisome proliferator–activated receptor-{gamma}2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes50 :876 –881,2001[Abstract/Free Full Text]
  31. Luan J, Browne PO, Harding AH, Halsall DJ, O’Rahilly S, Chatterjee VK, Wareham NJ: Evidence for gene-nutrient interaction at the PPAR{gamma} locus. Diabetes50 :686 –689,2001[Abstract/Free Full Text]
  32. ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol129 :687 –702,1989[Abstract/Free Full Text]
  33. Baecke JA, Burema J, Frijters JE: A short questionnaire for the measurement of habitual physical activity in epidemiologial studies. Am J Clin Nutr36 :936 –942,1982[Abstract/Free Full Text]
  34. Willett WC, Stampfer MJ, Rosher B, Bain C, Witchi J, Hennekens CH, Speizer FE: Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol122 :51 –65,1985[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
M. F. Crutchlow, B. Robinson, B. Pappachen, N. Wimmer, A. J. Cucchiara, D. Cohen, and R. Townsend
Validation of Steady-State Insulin Sensitivity Indices in Chronic Kidney Disease
Diabetes Care, July 1, 2007; 30(7): 1813 - 1818.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
O. Vaccaro, E. Lapice, A. Monticelli, M. Giacchetti, I. Castaldo, R. Galasso, M. Pinelli, G. Donnarumma, A. A. Rivellese, S. Cocozza, et al.
Pro12Ala Polymorphism of the PPAR{gamma}2 Locus Modulates the Relationship Between Energy Intake and Body Weight in Type 2 Diabetic Patients
Diabetes Care, May 1, 2007; 30(5): 1156 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Jaziri, S. Lobbens, R. Aubert, F. Pean, S. Lahmidi, M. Vaxillaire, I. Porchay, N. Bellili, J. Tichet, B. Balkau, et al.
The PPARG Pro12Ala Polymorphism Is Associated With a Decreased Risk of Developing Hyperglycemia Over 6 Years and Combines With the Effect of the APM1 G-11391A Single Nucleotide Polymorphism: The Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) Study.
Diabetes, April 1, 2006; 55(4): 1157 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
V. Paracchini, P. Pedotti, and E. Taioli
Genetics of Leptin and Obesity: A HuGE Review
Am. J. Epidemiol., July 15, 2005; 162(2): 101 - 114.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E.C. Tok, A. Aktas, D. Ertunc, E.M. Erdal, and S. Dilek
Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-{gamma}2 Pro12Ala genotype
Hum. Reprod., June 1, 2005; 20(6): 1590 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
ABDOMINAL OBESITY STUDY GROUP, F. E. VON EYBEN, J. P. KROUSTRUP, J. F. LARSEN, and J. CELIS
Comparison of Gene Expression in Intra-Abdominal and Subcutaneous Fat: A Study of Men with Morbid Obesity and Nonobese Men Using Microarray and Proteomics
Ann. N.Y. Acad. Sci., December 1, 2004; 1030(1): 508 - 536.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Kudo, A. Sugawara, A. Uruno, K. Takeuchi, and S. Ito
Transcription Suppression of Peroxisome Proliferator-Activated Receptor {gamma}2 Gene Expression by Tumor Necrosis Factor {alpha} via an Inhibition of CCAAT/ Enhancer-binding Protein {delta} during the Early Stage of Adipocyte Differentiation
Endocrinology, November 1, 2004; 145(11): 4948 - 4956.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kao, W.H. L.
Right arrow Articles by Brancati, F. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kao, W.H. L.
Right arrow Articles by Brancati, F. L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum